Regeneron pauses drug trial on sickest – Home Health Choices
For the second time, a examine testing an antibody drug…Latest Updates
Swiss pharma big Novartis on Tuesday reported greater income for the primary quarter as prospects dashing to purchase remedies throughout the coronavirus outbreak boosted the underside line.
Net revenue for the primary quarter rose 16 p.c to $2.1 billion whereas gross sales elevated by 11 p.c.
“COVID-19 did result in increased forward purchasing by customers, including at the patient level, as some patients filled prescriptions to cover a longer period of time,” Novartis stated.
The pharma big stated the pandemic had had “no material impact on our underlying business, financial condition, cash collections or liquidity”.
Novartis added it feared no provide chain disruptions for many of its portfolio “at this time”, and stated it anticipated to have the ability to fulfill demand from continued ahead purchases of medication as a result of pandemic.
Consequently, it maintained its outlook for the total 12 months 2020, through which it expects core working revenue to rise by a excessive single or low double-digit share.
Last week, Novartis introduced it will sponsor a medical trial within the US utilizing hydroxychloroquine to deal with sufferers hospitalised with COVID-19.
Novartis stated it had reached an settlement with the US Food and Drug Administration (FDA) to go forward with a section III medical trial with round 440 sufferers to judge whether or not the drug is environment friendly in treating coronavirus.
Novartis backs hydroxychloroquine trial in COVID-19 battle
© 2020 AFP
Novartis revenue up as world flocks to purchase medecine (2020, April 28)
retrieved 11 May 2020
This doc is topic to copyright. Apart from any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.